Indian Pharma Industry - Changing dynamics_Essay by Divya

INTRODUCTION

India is a rising economic power and an increasingly important Focus of innovation. India’s private-sector firms are fast improving the quality of their products and services and are rapidly expanding their global presence. As India grows as a center of global innovation, a new U.S.–India relationship is emerging—one where India is seen as both a partner and an effective competitor to the United States in the global marketplace. The knowledge-based nature of the pharmacy profession also presents a challenge for the educator as to the importance of research activity and the discovery of new knowledge. The knowledge-based nature of the pharmacy profession also presents a challenge for the educator as to the importance of research activity and the discovery of new knowledge. Traditionally, pharmacists utilized their scientific knowledge to develop the skills necessary to formulate, compound, and dispense medicines. As this is no longer the role of the pharmacist, the pharmacist arguably has been “deskilled” and does not have specialist skills.

SOME OF THE EXAMPLES OF FUTURE INNOVIATIONS.

1) Advisory board of pharmaceutical giants:

As patients take their health and through that their own future into their hands with the help of digital health, they also should be treated as equal partners in the hospitals, pharmacies – and even pharmacy companies. I believe that drug producers should have an advisory board including patients who have experience with the given company’s products. It would be easier to develop new products if the exact needs of the customers are well-known. Only with their help would it become possible to create a healthcare system that is futuristic even decades after the first plans were drawn. More and more healthcare conferences get the “Patients Included” badge. It means patients either speak at the event or are in the organizing  should include committee. Moreover, healthcare event organizers patients in the planning of their conferences.

2) Digital health “around the pill”:

Pharmacy companies around the globe are realizing that it is not enough anymore if they are producing and developing drugs. The trends show they have to go beyond the physical appearance of the medicine itself and offer a complete package. These are called already the “around the pill” digital offerings: digital health apps, devices or services that could be prescribed by a doctor or bundled with a drug.

For instance, Partners Healthcare Center teamed up with Japanese drug maker, Daichii-Sankyo to develop a “mobile wrap-around” for a Daichii Sankyo anti-coagulate drug prescribed for a trial fibrillation that will also work with other drugs. It involves a wearable monitoring device and an app, through which patients can receive positive feedback from their doctors and from the automated, personalized feedback generated by the app itself.

3) Test drugs on virtual organisms:

Testing drugs on humans and animals in the framework of costly and lengthy clinical trials are the past. Imagine that the characteristics of living organisms are so perfectly simulated that the clinical trial can be carried out in less time, with less money and still amazing results. This method is called an in silicone trial. It is basically an individualized computer simulation used in the development or regulatory evaluation of a medicinal product, device, or intervention. While completely simulated clinical trials are not feasible with current technology and understanding of biology, its development would be expected to have major benefits over current in vivo clinical trials.

HumMod is one of the most advanced simulations in this respect. It provides a top–down model of human physiology from whole organs to individual molecules. It features more than 1,500 equations and 6,500 variables such as body fluids, circulation, electrolytes, hormones, metabolism, and skin temperature. Humor aims to simulate how human physiology works.

ROAD AHEAD:

The laboratory and the marketplace;

Most pharmacy have complex supply chains that are under-utilized, inefficient and ill-equipped to cope with the sort of products coming down the pipeline. This new report predicts that in order to meet the demands of a fast evolving marketplace and the shift from patient to outcome, the pharmacy supply chain will need to undergo a radical overhaul.

Numerous forces are reshaping the environment in which the industry operates
By 2020, the more diverse product types and therapies with shorter product lifecycles; new ways for assessing, approving and monitoring medicines; increasing emphasis on outcomes; new modes of delivering healthcare where the care is pushed into the community and where access to information on patients will become as important as the products themselves; the growing importance of emerging markets; a greater public scrutiny impacting the ability to manage risk and compliance; and, tougher environmental controls and regulations will oblige companies to strategically reassess their supply chain approach.

Emerging technologies will increase the Manufacturing and distribution functions;
New technologies are emerging to help pharmacy companies manufacture a wider and more complex range of medicines, distribute them and also to speed the interface with the patient and getting closer than ever.

Collaboration between the parties involved in the healthcare provision will contribute to make the industry more efficient;
The supply chains for designing, manufacturing and distributing pharmaceuticals and medical devices plus those providing healthcare services will integrate so that all partners can see the full picture and help them plan ahead more accurately and cost-effective.

Right path of Companies of future;
There are two options for companies focusing on specialist therapies and treatments for orphan diseases and two options for companies focusing on mass-market medicines. Most companies will fall into one of those options although large players may cover both ends of the spectrum.

INCREASE OF QUALITY PHARMACY COLLAGES IN INDIA:

Anna University is not medical university With a drastic increase in the number of Pharmacy colleges in almost every part of the country, the intake of pharmacy students has increased to leaps and bounds in the colleges. In India, Pharmacy course is in pathetic condition and now too many private colleges are opened particularly in Tamil Nadu; there are 65 private pharmacy colleges and only 2 Govt. colleges. I addition, Anna University, Trichy conducts Integrated pharmacy course which is not recognized by Pharmacy Council of India because, in Tamil Nadu, all the Pharmacy colleges are comes and it is mainly deals with engineering courses.

JOB OPPORTUNITIES:

Last 2 to 3 years, students are not choosing the Pharmacy degree program for their study because of unemployment. Pharmacy course has named as "Professional Course" but compared to Medicine, no one recognizing this course as professional course. What is the current scenario of the pharmacy course particularly in Tamil Nadu, after graduating Bachelor degree, they are eligible for "Medical Representative" or to do Master Program.But to the core no efficient jobs are not available. so many students are suffering from many job problems.according to other department jobs there is no sufficient jobs are available. So most of the pharmacy students prefer to enter the teaching profession. And that’s why lot of collages is developing in our country. so no more blames on society there should be the change of thought between pharmacy students.

Pharmacy industry in future:

Now India’s Pharmaceutical industry is on a good growth path, Indian pharmaceutical manufacturing companies for making our presence known globally and competing with the pharmaceutical companies.

Recently Indian Pharmacy industry is likely to face stiff competition from other countries to get Abbreviated New Drug Application (ANDA) approval.

With new growth opportunities emerging in the pharmacy world, the pharmaceutical industry has shown great interest in India pharmacy sector due to its sustained economic growth, healthcare reforms and patent-related legislation. And India’s pharmaceuticals industry earns more than 70% of its revenues with the sale of generic drugs and more than 50% of its revenues come from exports.

According to IPI (Indian Pharmaceuticals Industry), pharmacy exports registered around $33 billion in revenues in 2016, of which a huge chunk of 50% was due to exports alone.

Finally Of the total pharmacy exports of $16.8bn during 2016-17, exports to the US commanded 40.6%, exports to Europe was 19.7%, Africa 19.1% and 18.8% was taken up by Asia.

GROWTH  STORY  IN  INDIA:

 Indian pharmaceutical industry had come a long way from nearly being non-existent in the 1960s to becoming one of the major suppliers of not just the generic drugs but also some complex formulations for the global market today. India’s pharmacy industry now occupies the 3^rd position in terms of volume and the 10^th place by value with a turnover of over $23billion. India also ranks among the top 5 fastest growing markets for the pharmaceuticals with an estimated compounded annual growth rate (CAGR) of 21 percent and is projected to be $75 billion market by 2020. This expansion has been a result of variety of factors.

 

A number of Indian pharmacy companies started out in the 1970s when the patent protection issues were quite unfavorable to the MNCs, giving an opportunity to Indian companies to get a foothold and create their niche for Indian as well as global markets. This was primarily led by generating low cost generic drugs by optimizing manufacturing processes and Active Pharmaceutical Ingredients (API) to supply other manufacturers. Today, generic drugs constitute over 70 percent of the Indian markets and the industry supplies more than 500 different APIs formulations to the specialized manufacturers. India now ranks among the most significant suppliers of the generics in the world, with a market share of about 40 percent in the US. India has more than 500 US Food and Drug administration (USFDA) ratified facilities, highest in the world outside the US. India is also the largest supplier of the generic drugs and infant vaccines such as measles and Hepatitis to the developing countries. Other factors that have contributed tremendously to its growth are enhanced medical infrastructure, greater health insurance coverage, better access to healthcare services, more per capita income and rise in prevalence and treatment of chronic diseases. Government has also played a supportive role in this growth, providing tax breaks to pharmacies, limiting the patenting to processes and setting up manufacturing SEZs, focused specifically on the industry. The cabinet has also approved 100 percent FDI through automatic route for manufacturing medical devices. The Make in India campaign further aims to strengthen this sector. However, Inspite of its smooth run and increasingly brighter prospects, the industry faces its own share of challenges and difficulties.

Pharma Franchise – A New Way to Rise In The Pharmaceutical Industry:

In the Indian circumstance in 10 years the Pharmaceutical business has seen a sea change in the way it uses to be run. The customary business methods are being changed with new innovative methodologies for business capable with the present brisk changing business circumstances in various divisions. Today, more people are joining the millionaire club in India and the Indian Pharmaceutical Industry has expected a key part other than IT. Today, more adolescents are set up to put it all out there on business and are moving from ordinary specialist to rapidly developing Employer.

Conclusion:

In this course you have had a brief introduction to how the drug-discovery process is conceived and initiated. You should by now have some appreciation of the intrinsic difficulties associated with developing a drug molecule from conception into a medicine suitable for clinical use and of how molecular modelling can be used in the drug discovery process. You should also by now have an elementary appreciation of the concept of pain and some understanding of the historical background to pain control. You should be aware that opioids, steroids and NSAIDs all work at the molecular level. Finally you should appreciate that anti-inflammation drug discovery requires a detailed understanding of the biochemical processes that constitute the inflammatory response.

Hope we (INDIA) will achieve more in Future.

FINALLY JAI HIND!!!! I LOVE INDIA .